Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab with CAPOX and Fianlimab or REGN7075 in Neoadjuvant Rectal Cancer
NCT07281768Phase 2Recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jul 2026
- Primary completion
- Jul 2030
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cemiplimab, fianlimab, dalmitamig in rectal cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Jul 2026; status: recruiting.
02
Drugs
cemiplimabfianlimabdalmitamig
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07281768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07281768.